Clinical Epidemiology (Nov 2022)

The Epidemiology, Treatment Patterns and Economic Burden of Different Phenotypes of Multiple Sclerosis in Italy: Relapsing-Remitting Multiple Sclerosis and Secondary Progressive Multiple Sclerosis

  • Perrone V,
  • Veronesi C,
  • Giacomini E,
  • Citraro R,
  • Dell'Orco S,
  • Lena F,
  • Paciello A,
  • Resta AM,
  • Nica M,
  • Ritrovato D,
  • Degli Esposti L

Journal volume & issue
Vol. Volume 14
pp. 1327 – 1337

Abstract

Read online

Valentina Perrone,1 Chiara Veronesi,1 Elisa Giacomini,1 Rita Citraro,2 Stefania Dell’Orco,3 Fabio Lena,4 Arrigo Paciello,5 Anna Maria Resta,6 Mihaela Nica,7 Daniela Ritrovato,7 Luca Degli Esposti1 1Clicon S.r.l. Società Benefit, Health Economics & Outcomes Research, Bologna, Italy; 2Dipartimento di Scienze della Salute, Università Magna Grecia di Catanzaro, Unita’ Operativa di Farmaco-logia Clinica e Farmacovigilanza, Azienda Ospedaliero-Universitaria “Mater Domini”, Catanzaro, Italy; 3ASL Roma 6, Rome, Italy; 4USL Toscana Sud Est, Grosseto, Italy; 5ATS Bergamo, Bergamo, Italy; 6Struttura Complessa di Farmacia Territoriale Area Vasta 1, Fano, Italy; 7Novartis Farma S.p.A, Origgio, Varese, ItalyCorrespondence: Valentina Perrone, CliCon S.r.l. Società Benefit, Health, Economics & Outcomes Research, Via Murri, 9, Bologna, 40137, Italy, Tel +39 3450316494, Email [email protected]: A retrospective analysis of real-world data was performed to assess the epidemiology and economic burden of multiple sclerosis (MS), relapsing-remitting MS (RRMS), and secondary-progressive MS (SPMS) in Italy.Patients and Methods: An observational study on administrative databases from a sample of Italian entities was carried-out. Between 01/2010– 12/2017, patients with ≥ 1 MS diagnosis code (ICD-9-CM:340 and/or exemption code:046) and/or ≥ 1 disease-modifying therapies (DMTs) prescription, were included. Among MS-cohort, SPMS patients were identified by ≥ 2 hospitalizations or by ≥ 2 drug prescriptions related to MS progression. MS patients not fulfilling SPMS criteria were included as RRMS. Mean annual healthcare costs were reported during follow-up and stratified by DMT treatment/untreatment.Results: Overall, 9543 MS patients were included; 8397 with RRMS and 1146 with SPMS. Estimated prevalence of MS was 141.6/100,000 inhabitants (RRMS 124.4/100,000 and SPMS 17.2/100,000). Mean annual cost for untreated and treated patient was respectively: € 3638 and € 11796 (MS-cohort), € 3183 and € 11486 (RRMS-cohort), € 6317 and € 15511 (SPMS-cohort). The first-line DMT treatment duration averaged 27.4 ± 22.8 months; the mean cost was 19004€ for the whole period. The second-line DMT treatment lasted on average 31.1 ± 24.5 months; the mean cost was 47293€ for the whole period.Conclusion: This study provided insights into the MS epidemiology in Italy and its economic burden. Healthcare costs associated with MS management were mainly driven by DMTs expenditure. A trend of higher healthcare-resource consumption was observed among SPMS-cohort.Keywords: real-world evidence, clinical practice, multiple sclerosis, epidemiology, healthcare resource consumption

Keywords